Bioelectronics Corp (BIEL)

[Rheeper]

Is Andy doing an R/S? If not, there is ZERO chance BIEL breaks a penny even after FDA clearance. Based on the current A/S. $0.10 implies a $2bn mkt cap or $6bn on a fully diluted shares basis. Look at the valuations of medical device stocks. BIEL would trade at unjustified 1000% - 10000% premiums to peers based on 1) poor corporate governance, 2) high leverage, 3) poor execution.

2.5m Actipatches a quarter? 10m Actipatches a year? This would be physically and mathematically impossible because of capacity constraints. Call the company to find out their manufacturing capacity.